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Abstract
The data described in this chapter consider some new information about the benefits of
vitamin D3 comparing the results obtained by the authors on the effects of vitamin D3
during oxidative stress with other works available in the literature. In particular, vitamin
D3  can  induce  a  concentration-dependent  increase  in  endothelial  NO  production
through eNOS activation consequential to the phosphorylation of p38, AKT, and ERK.
Additional information obtained by the author is about the ability of vitamin D3 to
prevent the endothelial cell death through modulation of interplay between apoptosis
and autophagy.  This  effect  is  obtained by inhibiting  superoxide  anion generation,
maintaining mitochondria function and cell viability, activating survival kinases (ERK
and Akt), and inducing NO production. The results also describe that vitamin D3 causes
human endothelial  cell  proliferation  and  migration  in  a  3-D matrix  through  NO-
dependent mechanisms. These findings support the role of vitamin D3 in the human
angiogenic process, suggesting new applications for vitamin D3 in tissue repair and
wound healing. Finally, that the authors have demonstrated the ability of vitamin D3 to
counteract negative effects  of oxidative stress in brain cells. These data suggest the
potential therapeutic use of vitamin D to treat or prevent degenerative brain diseases.
Keywords: active vitamin D, extraskeletal function, oxidative stress, endothelial cells,
neuronal cells
1. Introduction
Vitamin D, discovered as an essential nutrient for the prevention of rickets, is required for
optimal absorption of dietary calcium and phosphate [1]. Vitamin D plays an essential role
in  calcium  and  phosphate  metabolism  and  maintains  mineral  homeostasis  to  ensure
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metabolic functions and bone mineralization. The calcium requirement of the organism is
firstly  satisfied  by  dietary  calcium  intake  and,  when  this  is  not  sufficient,  by  calcium
mobilization from bone and renal reabsorption. Classical vitamin D–responsive tissues are
bones, intestine, kidney, and parathyroid glands [1–3] and in this case, vitamin D induces
skeletal effects. In addition many other organs respond to vitamin D, such as prostate, breast,
immune cells, skeletal muscle, cardiac tissue, parathyroid glands, skin, and brain; all these
organs express vitamin D receptor (VDR) and the enzyme 1α-hydroxylase and vitamin D
exert extraskeletal  effects  [4].  Vitamin D exerts its  activity through two mechanisms: the
hormone signaling, in which the biologically active form reaches target cells through the
bloodstream; and the autocrine/paracrine signaling, in which locally produced-vitamin D3
affects the surrounding cells [5].
A variety of research results from recent years have shown that vitamin D in its hormonally
active form, 1α,25-dihydroxyvitamin D [1α,25(OH)2D; calcitriol] is not only a regulator of
calcium and phosphate homeostasis, but has numerous extraskeletal effects. These include the
significant impact of the vitamin D hormone on the cardiovascular system, central nervous
system, endocrine system, and immune system as well as on cell differentiation and cell
growth [4]. The term “vitamin D” refers to two different forms playing an important role in
humans: vitamin D2 (ergocalciferol), which is made in some plants but largely in fungi [6],
and vitamin D3 (cholecalciferol), which is made by human skin when exposed to sunlight via
the UV irradiation of 7-dehydrocholesterol [6]. This photo-production is influenced by several
factors including ethnicity (skin pigmentation), UV exposure (latitude, season, use of
sunscreens, and clothing), and age. All these factors may reduce the ability to synthesize the
bioactive form of vitamin D. Moreover, low outdoor activity and unhealthy lifestyle habits are
also cause for a scarce vitamin D3 production. Conversely, excessive exposure to sunlight
degrades pre-vitamin D and vitamin D3 into inactive photoproducts. Many organs participate
in the synthesis of the bioactive form of vitamin D [7, 8]. Vitamin D3 needs two hydroxylation
steps in liver and kidney for its activation. The final product, hormonally active 1α,25-
dihydroxyvitamin D3 (calcitriol), arrives via the circulation to its target tissues and acts in a
genomic or nongenomic manner [9].
All genomic actions of vitamin D are mediated by the VDR. VDR is a transcription factor and
a member of the steroid hormone nuclear receptor family. VDR binding to its vitamin D
response elements (VDREs) causes the recruitment of coregulatory complexes required for its
genomic activity. These complexes can be both gene and cell specific, enabling the selectivity
of vitamin D3 action from cell type to cell type [8]. The profile of VDR binding sites and genes
activated by vitamin D3 varies from cell to cell with some albeit far from total overlap especially
when results with different time durations of vitamin D3 exposure are compared [10]. More-
over, these VDR binding sites can be anywhere in the genome, often many thousands of base
pairs away from the gene to be regulated. Generally, these sites are associated with binding
sites for other transcription factors [11, 12].
Vitamin D3 is also able to activate very rapid nongenomic mechanisms [8], lasting from seconds
to 10 minutes [13]. This mechanism involves signal transduction pathways including activation
of adenylyl cyclase-cAMP-protein kinase A and phospholipase C-diacylglycerol-inositol
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(1,4,5)-trisphosphate-protein kinase C signal transduction pathways [14]. Particularly, the
second messengers Raf (rapidly accelerated fibrosarcoma)/MAPK play an important role
because they may engage in cross-talk with the nucleus to modulate gene expression [13]. This
firstly identified nongenomic activation is associated with the rapid stimulation of intestinal
calcium transport called “transcaltachia” [15]. Successively, this effect was identified in the
chondrocytes of the bone growth plate [15] and in keratinocytes of the skin [16]. Identification
of the receptor for vitamin D3 has focused on the VDR itself albeit in a different configuration
to identify agonists able to induce nongenomic effects [17]. Interaction between vitamin D3 and
membrane-associated rapid response steroid binding protein (MARRS) has been studied as
well. These receptors are located in the membrane within caveolae/lipid rafts [18] where they
are poised to activate kinases, phosphatases, and ion channels.
The aim of this paper is to illustrate the most recent findings about the role of vitamin D3 as a
potent regulator of oxidative pathways.
2. Relevant extraskeletal applications
In a recent study, Berridge suggests the idea that vitamin D plays a crucial activity in keeping
the integrity of cell signaling pathways coining the term of “custodian of phenotypic stability”
[19]. The hypothesis supported is that a loss of this integrity could be explained by vitamin D
deficiency, and this represents a risk factor for different diseases. This role assigned to vitamin
D may depend on the regulation of the expression of nuclear factors involved both in physio-
logical control of ROS and in calcium signaling [19]. The hormonally active form of vitamin
D, 1α25(OH)2D3, influences the expression of various genes, whose products not only are
involved in the control of calcium and phosphate homeostasis, but are also able to interact with
a wide range of organs and target tissues different from those involved in calcium metabolism
[20]. Most experimental studies and meta-analysis showing a large amount of information
concluded that vitamin D supplementation is associated with a decrease in total mortality [21].
In effect, vitamin D3 is involved in a fine balance among organs and tissues that contributes to
the maintenance of the homeostasis of the human organism. For example, an important
function of vitamin D3 is to maintain normal parathyroid status, preventing proliferation of
parathyroid gland cells. Patients with renal failure-dependent vitamin D3 deficiency, in
presence of adequate calcium levels, may be affected by parathyroid hypertrophy with
consequent secondary hyperparathyroidism [22]. Moreover, vitamin D3 acts as a negative
endocrine regulator of the renin-angiotensin system. It enters the bloodstream and downre-
gulates renin production and stimulates insulin secretion from β-cells of the pancreatic islets
[1, 3]. Vitamin D3 is thought to possess positive effects on muscles, affecting the calcium
handling in the cells and promoting de novo protein synthesis. Vitamin D3 maintains calcium
balance in cultured muscle cells initially via inositol triphosphate induced-rapid ion release
from the sarcoplasmic reticulum and then through ion channels that allows calcium influx
from the extracellular compartment. Recently, vitamin D3 deficiency has been connected with
sarcopenia (age-related loss of muscle mass) mainly of type II skeletal muscle fibers. Vitamin
D supplementation reduces incidence of fractures, actually decreasing the number of falling
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[4, 7]. Sarcopenia was initially defined as “disease of the elderly” and a degenerative conse-
quence of ageing, but successively it can be also diagnosed at younger age [23]. Except for
ageing, risk factors for sarcopenia include female gender, low physical activity, low protein
intake, and vitamin D deficiency in both older and younger populations [23, 24]. Vitamin D
levels decline with age and cutaneous vitamin D levels are up to four times lower in older than
in younger individuals [25, 26]. Low vitamin D levels result in atrophy predominantly of the
type 2 muscle fibers and it has been associated with an increase in sarcopenia [27]. Finally, the
serum level of calcitriol is different in younger and elder people and it is related to incidence
of sarcopenia.
Vitamin D3 is a potent immunomodulator. For example, after a skin lesion, keratinocytes that
compose the mucocutaneous barrier upregulate VDR and 1α-hydroxylase expression in order
to improve immune defenses. Monocytes and macrophages act in the same way after a
Mycobacterium tuberculosis infection or exposure to lipopolysaccharides. An increased
cathelicidin and α-defensin 2 production results in all cases and these two proteins could
display their antimicrobial effects, promoting innate immunity. It has been hypothesized that
monocytes or macrophages may also release self-produced-vitamin D3 to act locally on
activated T and B lymphocytes, which are able to regulate cytokine and immunoglobulin
synthesis, respectively [3, 28]. The large number of effects of vitamin D3 regulating the immune
system plays a very important role in fighting infectious diseases [29]. Vitamin D3 enhances
the innate immunity against various infections [30], especially tuberculosis, influenza, and
viral upper respiratory tract infections [29]. Evidence exists about the potential antimicrobial
activity of vitamin D and its deficiency has deleterious effects on general well-being and
longevity. Vitamin D reduces the risk of infection in different manner: by modulating produc-
tion of antimicrobial peptides, by regulating local immune and immunoinflammatory
response, and by enhancing clearance of invading organisms. In addition, vitamin D consti-
tutes an inexpensive prophylactic option and possibly a therapeutic product either by itself or
as a synergic agent to the traditional drugs [31]. Ecological studies have shown that the
prevalence of certain autoimmune diseases was associated with latitude, suggesting a potential
role of sunlight exposure, and consequently vitamin D3 production, on the pathogenesis of
type 1 diabetes mellitus, multiple sclerosis and Crohn’s disease. The increased prevalence at
higher latitudes has been shown for multiple sclerosis (MS), inflammatory bowel disease,
rheumatoid arthritis, and type 1 diabetes [32–36]. In children with asthma, vitamin D levels
also seem to correlate positively with asthma control and lung function, and inversely with
corticosteroid use [37–39].
Many experimental data show that calcitriol stimulates apoptosis and differentiation and
inhibits angiogenesis and proliferation in tumor cells. Numerous association studies suggest
that serum vitamin D levels are inversely associated with the risk of many types of cancer.
Furthermore, in some studies of patients with cancer, an association between low vitamin D
levels and poor prognosis has been observed [40–42]. In breast, colon, and prostate cancer,
vitamin D3-VDR complex could arrest cell cycle in the G1-G0 transition, inducing p21 and p27
synthesis and/or stabilization, blocking cell growth and promoting cell differentiation. In TGF-
α/EGFR-dependent tumor, vitamin D3 can inhibit the growth inducing the recruitment of the
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activated receptor into early endosomes, and reducing growth signaling [21]. In monocytes
and osteoblast culture, it seems that the biologically active form of vitamin D3 could enhance
the expression of a suppressor of the oncogenic cyclin D1 and C/EBPβ. Moreover, vitamin D3
is able to regulate apoptosis. It could induce this process, like in breast cancer cells for example,
where it may modulate Bcl2 and Bax contents. However, it could also show antiapoptotic
effects, essential in normal tissue development and function. For instance, it protects kerati-
nocytes from UV-irradiation or chemotherapy-induced apoptosis and melanocytes from TNF-
α-mediated apoptosis. In normal keratinocytes, vitamin D3 induces cell differentiation and
maintains a calcium gradient necessary for the integrity of the permeability barrier of the skin.
Vitamin D3 represses tumor invasion and metastasis reducing matrix metalloproteinase
activity (MMP) and enhancing the expression of molecules with adhesive properties such as
E-cadherin [43]. However, calcitriol is a multifunctional steroid hormone able to regulate
signaling pathways related to cancer development and progression. In preclinical studies, it
was shown that vitamin D can promote cell differentiation and inhibit proliferation, angio-
genesis, and cell migration. Inconsistent results are found in epidemiological studies and in
early trials regarding clinical effects of vitamin D supplementation and cancer in terms of
prevention and impact in cancer-related mortality [44]. Vitamin D also exerts its effects on
cancer through nongenomic factors, modulating inflammatory cytokine expression. This is a
common element for cancer and neurodegeneration.
Figure 1. Vitamin D and cardiovascular risk (adapted from [48]).
Another important feature of vitamin D is the mitochondrial detoxification, well known as
antioxidant activity. Especially, vitamin D and polyphenols, seem to be promising therapeutic
tools for inhibiting radical oxygen species (ROS) formation and arresting cytokine-mediated
inflammation [45].
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Vitamin D status varies with age [46]. Serum levels of calcitriol are normal from 75 nM,
insufficient from 50 to 75 nM, and deficient if less than 50 nM [47]. These serum concentrations
depend on sunlight exposure, dietary intake, capacity of the skin, and influence various human
diseases (cardiovascular and neurological), as reported in this manuscript (Figures 1 and 2).
Figure 2. Vitamin D and neurological diseases (adapted from [49]).
2.1. Cardiovascular and cerebral risk
In humans, the relationship among low levels of vitamin D3, hypercalcemia, osteoporosis,
vascular calcification, and cardiovascular diseases has been extensively studied. Vitamin D3
deficiency is significantly associated with cardiomyopathy and increased risk of cardiovascu-
lar disease with consequent mortality in humans [8]. The prospective Intermountain Heart
Collaborative Study revealed that vitamin D3 blood levels below 15 ng/mL compared to
vitamin D3 above 30 ng/mL are associated with significant increases in the prevalence of type
2 diabetes mellitus, hypertension, hyperlipidemia, and peripheral vascular disease, coronary
artery disease, myocardial infarction, heart failure, and stroke, as well as with incident death,
heart failure, coronary artery disease/myocardial infarction, and stroke [50].
Several data are available from studies in mouse animal model. Heart-VDR null mice show
myocardial hypertrophy, while VDR and CYP27B1 null mice develop hypertension as well
and display increased production of renin, contributing probably to early atherosclerosis
onset [51]. Vitamin D3 may protect against atherosclerosis inhibiting macrophage cholesterol
uptake and foam cell formation, and reducing vascular smooth muscle cell proliferation and
expression of adhesion molecules in endothelial cells. Recently, elevated levels of PTH emerged
as a possible risk factor for cardiovascular diseases since they could promote development of
hypertension; in addition, hyperparathyroidism could cause heart hypercontractility and
calcification of the myocardium. Vitamin D3 could overcome these processes, promoting, for
example, synthesis of anti-inflammatory cytokines [4]. Severe vitamin D3 deficiency in humans
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is associated with cardiomyopathy [52], and in a number of large epidemiologic studies, the
association of increased cardiovascular disease risk with low vitamin D3 blood levels has been
found [53]. Obesity, a condition associated with cardiovascular disease [54], is related with a
low vitamin D3 status due to a sequestration and volumetric dilution of the lipophilic vitamin
D3 in the fat tissue [3, 55, 56]. Many studies suggest a biological beneficial effect of vitamin D3
on cardiovascular risk factors and cardiovascular health. For example, in a recent study
performed on Framingham Offspring Heart Study participants [57], vitamin D3 deficiency was
associated with increased cardiovascular risk, above and beyond established cardiovascular
risk factors. In another study, performed on elderly subjects, an association between low serum
vitamin D3 levels and high arterial blood pressure was found [58]. In addition, vitamin D3
insufficiency/deficiency is associated with myocardial infarction, congestive heart failure, and
calcific aortic stenosis, which can lead to the massive vascular calcification seen in chronic
kidney disease. Recent clinical studies demonstrated that vitamin D3 may cause regression of
cardiac hypertrophy, reduces cardiovascular morbidity, and mortality in patients who
frequently suffer from atherosclerosis [59, 60] and it may improve the cardiac structure and
function [61].
The VDR is present in endothelium, vascular smooth muscle, and cardiomyocytes [55, 57] and
may protect against atherosclerosis through the inhibition of macrophage cholesterol uptake
and foam cell formation, the reduction of vascular smooth muscle cell proliferation, and the
decrease of expression of adhesion molecules in endothelial cells [55] and through inhibition
of cytokine release from lymphocytes [57]. Several meta-analyses indicate an inverse associa-
tion between vitamin D3 status and hypertension, and the antihypertensive effects were
associated with a rate in vitamin D3 levels after dietary supplementation or UVB exposure [62–
66]. Mechanistically, this effect could be partly mediated by vitamin D3’s capability to suppress
the levels of PTH, which is the cause of arrhythmias, myocardial hypertrophy and increasing
blood pressure [67], and the levels of renin [67, 68]. As far as endothelial effects are concerned,
it has been demonstrated that vitamin D3 modulates vascular tone by means of a reduction in
calcium influx into the endothelial cells followed by a decrease in endothelium-derived
contracting factors production. Vitamin D3 exerts its physiological effects acting on VDR
through both genomic and nongenomic mechanisms, regulating cellular proliferation,
differentiation, apoptosis, and angiogenesis in local tissue [69–71]. In particular, many vascular
effects, such as increased expression of Ca-ATPase, induction of contractile protein synthesis,
and, hence, increased vascular resistance have been reported. Vitamin D3 is a modulator of
vascular wall growth as well [72] and induces a decrease in the expression and/or secretion of
proinflammatory and proatherosclerotic factors in the endothelium [73]. The role of endothe-
lium as a target of vitamin D3 is demonstrated by the study published by Zehnder et al. [74],
in which the expression of mRNA and protein for lα-hydroxylase in human endothelium was
shown for the first time. Altogether, these findings demonstrated the direct effects of vitamin
D3 on endothelial function, whose alteration plays an important role in the development of
atherosclerosis. Endothelial cells are capable of synthesizing vitamin D3 as results from the
expression of mRNA and protein for the enzyme 25(OH)D3-1α-hydroxylase [75]. Moreover,
studies elsewhere have demonstrated the presence of intracellular vitamin D3 receptors within
endothelial cells (VDR) [76]. Endothelial cells can synthesize vitamin D3 due to the expression
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of the key biosynthetic enzyme 25 (OH)D3-1a-hydroxylase [74]. Because of the presence of both
vitamin D3 and VDR in endothelial cells and the key role of nitric oxide (NO) in the endothelial
physiology, it is possible to hypothesize an interaction between vitamin D3 and NO capable of
influencing proliferation and migration of endothelial cells [75]. Although the relationship
among vitamin D3, endothelium, and cardiovascular disease is well established, little is known
about the effect of vitamin D3 on endothelial NO production. In addition, several recent studies
have postulated anti-inflammatory, immunomodulatory, and neuroprotective functions for
vitamin D3. A meta-analysis examining the association between vitamin D3 status and the risk
of cerebrovascular events, including more than 1200 stroke cases, found that the pooled relative
risk for stroke was 52% higher when comparing 25(OH)D levels ≤12.4 ng/mL with 25(OH)D
levels >18.8 ng/mL [77].
As concerned to cerebral effects, the observed widespread distribution of 1α-hydroxylase and
the nuclear VDR in both neurons and glial cells suggest that vitamin D3 may have autocrine
and paracrine properties in the brain [78, 79]. VDR is highly expressed in multiple brain
regions [80] in the animal [81] and human [82] brain, particularly in the pontine-midbrain area,
cerebellum, thalamus, hypothalamus, basal ganglia, hippocampus, olfactory system, and the
temporal, orbital, and cingulate areas of brain cortex [83]. Mounting evidence indicates that
vitamin D3 and its receptors play an important role in the brain, ranging from neuroprotection
to immunomodulation [84]; cells proliferation and differentiation [85], and plays an important
role both in developing [86] and adult brain [80]. Vitamin D3 can exert these effects since it is
able to cross the blood-brain barrier and can bind to VDR within the brain [87, 88]. Upon
binding, VDR undergoes a conformational change to form a complex with a retinoid X receptor
that controls genic expression [89, 90]. More recent papers demonstrate that gestational
vitamin D3 deficiency induces long-lasting alterations in the brain structure, including changes
in volume, cell proliferation and reduction in the expression of nerve growth factors (NGF),
glia-derived neurotrophic factor (GDNF) and neurotrophins 3 and 4 [80, 83, 91]. Moreover,
vitamin D3 protects neurons against NMDA, glutamate, 6-hydroxydopamine, and reactive
oxygen species [92, 93]. It has been hypothesized that vitamin D3 exerts its neuroprotective
effects via the modulation of neuronal Ca2+ homeostasis, in particular through the downregu-
lation of the L-type voltage-sensitive Ca2+ channel in hippocampal neurons against excitotoxic
insults [80], accompanied by an increase in VDR density. Vitamin D3 is able to inhibit proin-
flammatory cytokine and NOS [94] typically increased during various insults or disorders,
such as ischemia and reperfusion, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis,
and experimental autoimmune encephalomyelitis. Early vitamin D3 deficiency may be
considered as a risk factor for a number of neurological disorders including schizophrenia,
autism [88, 95], multiple sclerosis, Parkinson’s disease, and stroke [77, 89]. Vitamin D3
deficiency is associated with reduced cognitive function, which is an important issue for stroke
patients [96]. Moreover, in the rat model of stroke, vitamin D3 supplementation has been found
to reduce brain damage [97] and consequent seizures [77] and oxidative stress [98]. For this
reason, it should be very important to study the role of vitamin D3 in counteracting negative
effects of oxidative stress in vitro brain, also in association with stem cell. So, vitamin D3 may
be considered as a potential drug for the treatment of neurodegenerative disorders.
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3. Oxidative stress and injury
Xiang et al. [99] showed the ability of vitamin D3 to stimulate endothelial cell proliferation and
to inhibit apoptosis by increasing endothelial nitric oxide synthase (eNOS) expression and
nitric oxide (NO) production. NO plays a key role in cardiovascular physiology [100], and its
production in the heart by eNOS phosphorylation represents an important regulating factor
of both myocardial perfusion after ischemia and myocardial contractility. This has important
effects on cardiac cell functions such as oxygen consumption, hypertrophic remodeling,
apoptosis, and myocardial regeneration [101–103]. The discovery of NO as a signaling
molecule in the cardiovascular system was published in 1998 [104] and it is now recognized
as an endogenous vasodilator and an antioxidant factor able to regulate the vascular endo-
thelium supporting its anticoagulant and antithrombogenic capacities, maintaining vascular
tone and preventing vascular smooth cell proliferation [105]. NO acts as a signaling molecule
by binding to ferrous heme within metalloproteins (such as soluble guanylate cyclase, sGC,
cytochrome c oxidase, and hemoglobin). The most important action mechanism of NO is the
interaction with heme of the sGC in smooth muscle cells adjacent to the endothelium, cata-
lyzing the conversion of guanosine triphosphate (GTP) to cGMP [106]. cGMP-dependent
protein kinases promote the opening of calcium-dependent potassium channel and determine
hyperpolarization of the cell membrane of smooth muscle, thus inhibiting cytosolic calcium
influx and promoting cell relaxation and vasodilation. Alternatively, NO can determine
molecular modifications. Since it is a highly diffusible molecule in tissues and physiological
fluids with a very short half-life (few seconds), it rapidly reacts with superoxide anion (O2−) to
form peroxynitrite (ONOO−). ONOO− oxidizes DNA, proteins, lipids, and BH4, uncouples
eNOS and limits NO production. ONOO− directly influences the dilatory capabilities of the
arteries and disrupts NO-induced sGC-mediated signal transduction [107]. Nevertheless, NO
could be transported by protein carriers or stored locally and cause remote and long-lasting
effects in the cardiovascular system [108, 109]. In addition NO is able to enhance endothelial
cell survival, proliferation, and migration [110, 111]. Furthermore, NO signaling depends on
its own concentration. Thomas and colleagues demonstrated in MCF7 cells (human breast
adenocarcinoma cell line) that NO levels ranging from 10 to 30 nM lead to extracellular signal-
regulated kinases (ERK) phosphorylation. This effect is due to a cGMP-dependent process,
mediating proliferative and protective effects. It has been demonstrated that low NO levels,
below 1 nM, are sufficient to obtain this response in endothelial cells. When the NO concen-
tration is between 30 and 60 nM, Akt phosphorylation occurs. This antiapoptotic mechanism
depends on Bad and caspase-9 phosphorylation. Hypoxia-inducible factor-1α (HIF-1α) is
stabilized when NO is at a high concentration (about 100 nM) and protects against tissue injury,
while at 400 nM p53 is posttranslationally modified, resulting in growth arrest or apoptosis.
Signal transduction cascades react accordingly to NO not only in terms of concentration but
also in terms of duration of exposure with different threshold sensitivities, resulting in distinct
phenotypic responses. Indeed, HIF-1α is an immediate but transient responder and protein
disappears when the NO concentration falls under the minimum threshold. On the contrary,
p53 has a delayed response that takes several hours to occur but is sustained long after NO
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exposure [112]. Despite the differences in clinical manifestations and neuronal vulnerability,
the pathological processes appear similar in neurodegenerative pathways as well.
Cell death and neurodegenerative conditions have been linked to oxidative stress and
imbalance between generation of free radicals and antioxidant defenses. Multiple sclerosis,
stroke, and neurodegenerative diseases have been associated with the reactive oxygen species
and nitric oxide [113]. Recent findings about the production of the reactive oxygen and nitrogen
species by NADPH oxidases and nitric oxide synthases and the essential role of glutathione
(γ-glutamyl-l-cysteinylglycine) in redox homeostasis demonstrate the importance of these
substances in neuronal degeneration. Redox signaling has a profound impact on two tran-
scription factors that modulate microglial fate, nuclear factor kappa-light-chain-enhancer of
activated B cells, and nuclear factor (erythroid-derived 2)-like 2, master regulators of the pro-
inflammatory and antioxidant responses of microglia, respectively. The relevance of these
proteins in the modulation of microglial activity and the interplay between microglia and
oxidation has been described. Finally, the relevance of ROS in altering blood-brain barrier
permeability is reported. ROS originates in the mitochondrial electron transport chain (mETC)
or are produced by NADPH oxidases (NOX) by an incomplete one-electron reduction of
oxygen. Three major ROS exist: superoxide anion (O2−), hydrogen peroxide (H2O2), and
hydroxyl radical (OH). In cellular respiration, most of O2 generates H2O2 through enzymes of
the superoxide dismutase (SOD) family, enclosed copper-zinc superoxide dismutase (SOD1 or
Cu, Zn-SOD) present in the intermembrane space and in the cytosol, manganese superoxide
dismutase (SOD2 or Mn-SOD) present in the mitochondria matrix, and SOD3 present in the
extracellular matrix. Hydrogen peroxide could subsequently be converted to the hydroxyl
radical by ferrous, or a final reducing step could convert it to water by catalase, glutathione
peroxidase, and peroxyredoxin III activity.
In endothelial cells, ROS into the cytosol could stimulate further ROS production by NOX2
through redox-sensing protein kinase C (PKC) isoforms and Src family kinases activation [114,
115]. Recent examples of the importance of these findings about ROS and NO in the onset or
progression of neurodegenerative diseases are also showed [116]. Three NO-synthase isoforms
could produce NO: (1) NO-synthase I (or neuronal, nNOS, NOS-1) expressed in neurons and
skeletal and smooth muscle; (2) NO-synthase II (or inducible, iNOS, NOS-2) in immune cells;
and (3) NO-synthase III (or endothelial, eNOS, NOS-3) in cardiomyocytes and platelets and,
predominantly, in endothelial cells [109, 117]. NOS isoforms generate NO at different rates:
eNOS and nNOS produce a low concentration of NO, leading to physiological processes
regulation, while iNOS generates a high NO concentration in response to inflammatory
stimuli, such as in activated macrophages, to establish cytotoxic effects and antipathogen
reactions [118]. eNOS is a Ca2+/calmodulin dependent enzyme and contains an N-terminal
oxygenase and a C-terminal reductase domain, linked by a calmodulin binding sequence. It
works as a homodimer to synthesize NO and L-citrulline from L-arginine and oxygen. In the
presence of several cofactors, such as nicotinamide adenine dinucleotide phosphate (NADPH),
flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), heme, tetrahydrobiopterin
(BH4), and zinc, it catalyzes a five-electron oxidation of one of the guanidino nitrogens of L-
arginine. Since it is a gas, NO then diffuses to the vascular smooth muscle cells and reacts with
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sGC, leading to cGMP-mediated vasodilatation. In endothelial cells, after enzymatic acylation,
myristoylation and reversible palmitoylation, eNOS is predominantly located in the plasma
membrane and in the Golgi apparatus associated with caveolin-1 located in caveolae, whose
binding inhibits the activity of the enzyme [108, 109]. Two mechanisms leading to eNOS
activation and involving G protein coupled receptors and heterotrimeric G protein have been
explained: intracellular Ca2+ mobilization through phospholipase C (PLC) pathway, and
phosphatidylinositol-3-kinase (PI3K)/Akt pathway [119, 120]. An increase in intracellular
calcium concentration, indeed, is a critical determinant that causes eNOS dissociation from
caveolin-1, leading to the activation of the enzyme. Moreover, serine, threonine, and tyrosine
phosphorylation regulate eNOS activity, either enhancing or suppressing it, depending on the
residue and the domain that are involved. Several eNOS agonists such as VEGF, bradykinin,
and adenosine triphosphate (ATP) promote the activation of phosphorylation. eNOS expres-
sion and activation is also sensitive to shear stress caused by blood flow; low shear stress
determines lower NO production, increasing atherosclerotic plaque formation [108, 109].
Endothelial dysfunction should be considered as endothelial activation from a quiescent
phenotype and it is identified as an initial step in the development of CVD. This is characterized
by reduced NO bioavailability that predisposes to vasoconstriction and thrombosis [121].
Several factors can contribute to this process, such as decreased eNOS expression, presence of
eNOS antagonist, low L-arginine or BH4 concentration, increased NO degradation or ROS
production, exposure to inflammatory cytokines and growth factors [95]. Indeed, the funda-
mental change is a switch in the signaling from an NO-mediated silencing of cellular processes
toward activation by redox signals. The generation of hydrogen peroxide that could react with
cysteine groups in proteins alters their function, determining transcriptional factor phosphor-
ylation, induction of nuclear chromatin remodeling, and protease activation. eNOS, normally
involved in the maintenance of the quiescent state of the endothelium, could be uncoupled, in
the case of substrate L-arginine deficiency. Consequently, superoxide formation occurs if the
key cofactor tetrahydrobiopterin is not present, or hydrogen peroxide production is establish-
ed. The mitochondria are a source of ROS during hypoxia or conditions of increased substrate
delivery, such as in obesity-related metabolic disorders or type II diabetes, which are charac-
terized by hyperglycemia and increased circulating free fatty acids. The interaction between
ROS and NO results in further endothelial activation and inflammation [122].
4. Protective effects of vitamin D
Although the relationship among vitamin D3, endothelium, and cardiovascular disease is well
established, until recently little was known about the effect of vitamin D3 on endothelial NO
production. NO plays a key role in cardiovascular physiology [100], and its production in the
heart by eNOS phosphorylation represents an important regulator of both myocardial
perfusion after ischemia and myocardial contractility and has important effects on cardiac cell
functions such as oxygen consumption, hypertrophic remodeling, apoptosis, and myocardial
regeneration [101–103]. In addition, NO is able to enhance endothelial cells survival, prolifer-
ation, and migration [123]. In recent works, cells proliferation has been evaluated in low serum
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conditions to synchronize cell culture after 24 or 48 h in starvation medium in the presence or
absence of vitamin D (1–10–100 nM) for porcine aortic endothelial cells (PAE) [123] and human
umbilical vein endothelial cells (HUVEC), respectively [124, 125]. Vitamin D3 induces a
significant dose-dependent increase in cell growth at all concentrations tested. The maximal
effect is reached by stimulating PAE cells with 10 nM vitamin D3, while at the highest concen-
tration tested (100 nM) the vitamin D3 effect on cell proliferation is less potent (p < 0.05). The
observed cellular density is almost doubled compared to control samples for PAE cells (690
± 210 cells/mm2 vs 354 ± 84 cells/mm2, p < 0.01) and HUVEC. Proliferation assays were also
performed in the presence of L-NAME, the arginine analog inhibiting NO synthesis, in order
to evaluate NO involvement. In these conditions, vitamin D3 is no more able to induce cell
proliferation, in all cell types. The presence of L-NAME does not alter control cell proliferation,
whereas it completely reverts vitamin D-induced cell proliferation. The effective involvement
of VDR in these effects has been demonstrated as well. HUVEC were stimulated with the VDR
ligand ZK159222. Under these conditions, a significant decrease in vitamin D–induced cell
proliferation has been observed, confirming the role of VDR in the effects mediated by
vitamin D3. In addition, an increase in cell mitosis has been observed only in vitamin D3 treated
specimens and not in samples with L-NAME. Cell migration has been evaluated in a three-
dimensional model by an anionic hydrogel made of gelatin and polyglutamic acid, which has
previously been described as a good substrate for cell growth [126, 127] and was lean on 70%
confluent cell monolayers. PAE migration, evaluated by counting the cells migrated in the 3-
D matrix for 7 days, increases significantly only in the presence of 100 nM vitamin D3 (p < 0.05).
HUVEC migration increases significantly only in the presence of 10 nM and 100 nM vitamin
D3 (p < 0.05 and p < 0.01 respectively). L-NAME treatment does not affect control cell migration,
while it significantly reduces vitamin D-induced hydrogel invasion and ZK159222 reduces the
vitamin D-induced migratory effect. Extracellular matrix degradation is one of the main steps
in cell migration; for this reason, vitamin D affects on MMP-2 expression in the conditioned
medium of cells migrating into the 3-D hydrogel matrix after 7 days has been evaluated by
gelatin zymography. Vitamin D3 addition to PAE culture medium increases MMP-2 production
in a dose-dependent manner. In HUVEC, gelatin zymography demonstrates a statistically
significant increase in MMP-2 activity in all the vitamin D-treated samples. This effect is more
evident in samples stimulated with 100 nM vitamin D3 (p < 0.01). The increase in MMP-2
expression appears to be NO dependent, as L-NAME treatment totally abrogates vitamin D3
effects on MMP-2 expression, according to the above described results for cell migration. In
this context it is very important verify the effect of vitamin D3 in HUVEC on NO production
and the intracellular pathways activated by vitamin D3 leading to eNOS activation.
Vitamin D3 is able to stimulate NO production in HUVEC in a dose-dependent manner
accompanied by a significant increase in the level of phosphorylation of intracellular kinases.
The administration of vitamin D3 induced the highest production of NO, acutely increased the
phosphorylation of eNOS, p38, AKT, and ERK, which are known to be involved in the
intracellular signaling leading to NO production [128]. The effects were prevented by L-NAME
or specific protein kinase inhibitors such as SB203580, wortmannin, and UO126 related to p38,
AKT, and ERK in endothelial cells [129]. Another important finding is the demonstration of
the involvement of VDR in vitamin D-induced endothelial NO production [76]. This fact is
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shown by VDR antagonist ZK159222 and by VDR agonist ZK191784. These data on the role of
VDR ligands on endothelial NO production add new information on the possible therapeutic
role of these substances. VDR plays an important role in modulating cardiovascular function
and early interventional studies in humans demonstrated that VDR analogs therapy seems to
be more effective than native vitamin D supplementation in modulating cardiovascular disease
risk factors [130]. It is noteworthy that vitamin D3 response occurs within seconds and, for this
reason, it appears to be a nongenomic effect. This fact about the role of the concentration of
vitamin D3, is also important to explain same data reported in the literature about the ability
of vitamin D3 to prevent myocardial ischemia in patients with a decreased serum vitamin D3
concentration as reported in a case-control study in 1990 on 179 patients [131] in which the
odds of having a myocardial infarction increased along. In another study, Giovannucci et al.
[132] demonstrates that men with vitamin D3 deficiency had a higher risk of myocardial
infarction compared with those with normal vitamin D3 concentration.
Recent investigations on cardiac myocytes showed that ROS produced by mitochondrial and
oxidative stress can cause multiple changes in the cell structure and the function that are
associated with a failing heart [133] and apoptosis [134] or autophagy [135]. On the other hand,
ROS, along with NO, show antiapoptotic effects involving several signaling pathways; for
example, not only activates proapoptotic signals [135] but also potently induces autophagy
[136]. The functional role of autophagy during ischemia/reperfusion is complex, because its
pathophysiological functions depend on the severity and duration of ischemia (hypoxia) and
the consequent tissue damage during reperfusion in the heart. The level of autophagy may
determine whether autophagy itself is protective or detrimental in response to ischemia/
reperfusion injury in the heart [137]. Vitamin D3 is able to induce autophagy in various human
cell types. The signaling pathways regulated by vitamin D3 include, for example, Bcl-2, beclin
1, and mammalian target of rapamycin (mTOR) [138]. The interplay between autophagic and
apoptotic pathways is a crucial point to determine the initiation of programmed cell death and
whether the members of the beclin 1 and Bcl-2 family were involved. Beclin 1 directly interacts
not only with Bcl-2 but also with other antiapoptotic Bcl-2 family proteins such as Bcl-xl, and
Bcl-2 was able to inhibit the beclin 1-dependent autophagy [139]. It has been clearly demon-
strated that administration of vitamin D3 to endothelial cells before induction of an oxidative
stress can improve cell viability [20]. The mechanisms involved include the prevention of free
oxygen radical release and the modulation of the interplay between apoptosis and autophagy.
These effects were also accompanied by NO production and preservation of mitochondrial
function. HUVEC cultures received an oxidative stress by means of H2O2. This method is
widely used to reproduce a cellular damage similar to what occurs in myocardial ischemia/
reperfusion injury [20]. In light of these data, a cardioprotective role of vitamin D3 against the
ischemic injury can be hypothesized. As observed in NO production and MTT tests, the effect
induced by VDR agonist ZK191784 is greater than the one observed after vitamin D3 alone.
Moreover, the combined administration of the two VDR agonists (Vit D and ZK191784)
induced an amplified effect. These beneficial effects were observed when VDR agonists were
administered before the induction of oxidative stress. This fact supports the hypothesis that
vitamin D3 is able to counteract the negative effects of the oxidant event on endothelial cells,
increasing cell viability. In addition, NO release induced by vitamin D3 during oxidative stress
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is able to protect cells from death. This result is demonstrated by the observation that the rate
of NO production was below 2¼M/s. This threshold prevents the opening of the mitochondrial
transition pore and the release of cytochrome C and avoids mitochondrial collapse leading to
cell death [140]. The antiapoptotic effects of NO and ROS involved several signaling pathways,
and the interplay between autophagic and apoptotic pathways is a crucial point to determine
the starting of programmed cell death. Another important finding is that pretreatment with
vitamin D3, alone or in combination with ZK191784, is able to reduce the apoptosis-related
gene expression (Bax, caspase-3, caspase-9, caspase-8, and cytochrome C), involving both
intrinsic and extrinsic pathways. These findings were confirmed by immunohistochemistry
analysis of annexin V and TUNEL assay in which we observed a signal reduction. At the same
time, activation of pro-autophagic beclin 1 and the phosphorylation of ERK1/2 and Akt,
members of the reperfusion injury salvage kinase pathway, have been shown, indicating a
modulation between apoptosis and autophagy. Moreover, vitamin D3, alone or in combination
with ZK191784, administered before the oxidative stress, is able to prevent the loss of mito-
chondrial potential and the consequent cytochrome C release and caspase activation. In
addition, vitamin D3 alone or in combination with ZK191784 was able to prevent the MPTP
opening caused by H2O2. These findings depend on changes of mitochondria-trapped calcein
intensity and on effects of cyclosporin A, which inhibits MPTP opening, modulating the
cyclophilin D activity [141].
Oxidative stress and the consequent mitochondrial fragmentation are involved in several
neurodegenerative disorders as well [142–144]. Oxidative stress results from Fenton reaction,
which generates ROS and consequently induces irreversible damage to DNA, RNA, proteins,
and lipids [145]. Thus, there is compelling evidence that the neuroprotective action of vita-
min D3 is revealed through neuronal calcium regulation, antioxidative pathway, immunomo-
dulation, and detoxification. Vitamin D3 along with its metabolites influences directly or
indirectly almost all metabolic processes such as proliferation, differentiation, apoptosis,
inflammatory processes, and mutagenesis. Such multifactorial effects of vitamin D3 can be a
profitable source of new therapeutic solutions for two radically divergent diseases, cancer and
neurodegeneration [146]. The role of vitamin D3 to prevent iron damage in neuroblastoma cells
BE(2)M17 has been recently studied [147]. In this research, the mechanisms involved in
neurodegeneration, such as cell viability, ROS production, and the most common intracellular
pathway have been studied. The BE(2)M17 cell line is an alternative neuronal cell model widely
used in neuroscience research [148]. The beneficial effect of vitamin D3 consists of a significant
decrease in iron accumulation and ROS production, two important co-factors of neurodegen-
eration [149]. The effects of vitamin D3 have been observed in BE(2)M17 cells through the
activation of the VDR receptor and for this reason, the mechanisms underlying the protective
effects of vitamin D3 may be hypothesized to have genomic origin. Moreover, under these
conditions, the survival pathway (ERKs) was also activated in presence of vitamin D3. In
addition, in these experiments Fe3+-dependent activation of principal neurodegenerative
biomarkers, such as p53 [150], Ki67 [151] and c-Myc [152], has been confirmed. A novel finding
is represented by the demonstration that pre-treatment with vitamin D3 is able to significantly
counteract tumoral biomarker activation.
A Critical Evaluation of Vitamin D - Basic Overview60
5. Conclusions
The results described herein highlight that vitamin D3 stimulates endothelial cell proliferation
and migration in a 3-D matrix and that these phenomena depend on NO production. Further-
more, this work adds new information to the debate on the benefits of vitamin D3 supplemen-
tation. Indeed, it has been shown for the first time that vitamin D3 may prevent endothelial cell
death through the modulation of the interplay between apoptosis and autophagy. This effect
is obtained by inhibiting superoxide anion generation, maintaining mitochondria function and
cell viability, activating survival kinases, and inducing NO production. In the recent years, the
knowledge about vitamin D3 has improved and its implications have extended beyond its
classical role in bone health in either fields of basic research as well as in human clinical trials,
showing the relevance of the vitamin D3 system. Until now, the available data are significant
and confirm its essential role in several physiological and preventive functions. A greater
understanding of vitamin D3 system will shed new light on the use of vitamin D3 supplemen-
tation in very promising fields such as tissue repair, wound healing, and prevention of the
human angiogenic process. The former shows that the association between vitamin D3 status
and cardiometabolic outcomes is uncertain and that no clinically significant effect of vitamin
D3 supplementation at the dosages given is found. The latter suggests that vitamin D3 dietary
supplements at moderate to high doses may reduce cardiovascular disease risk. Vitamin D3
along with its metabolites influences directly or indirectly almost all metabolic processes such
as proliferation, differentiation, apoptosis, inflammatory processes, and mutagenesis. Such
multifactorial effects of vitamin D3 can be a profitable source of new therapeutic solutions for
two radically divergent diseases as cancer and neurodegeneration [134]. The discussed results
could be relevant in the light of the use of vitamin D3 to promote supplementation or to adjust
therapeutic strategies in neurodegenerative disorders.
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